Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing itself at it
The model's full reasoning — Q4 2015 call → NOWe need to determine if management describes an offering with both: (1) customer response running ahead of what company prepared for, and (2) company responding now by putting more behind it. Also offering is small relative to total business. Let's scan transcript for such an offering. Key candidates: TruVue container (clear can), flexibles, i6, EvoCan, composite cans, etc. Look for statements about demand exceeding preparation and current expansion. From transcript: Jack Sanders mentions TruVue container: "we're still shooting for end of first quarter, early second quarter release." That's future. Not yet current uptake. Also "we've had three or four new contact from potential customers" - that's interest, not orders. So no. Flexibles: "flexible packaging business experienced sales growth of 9.8% and expanded operating profit by 21.7% through market share expansion, price cost management and solid productivity improvements. We are adding a new triplex laminator and a new rotogravure press during the first half of this year and we expect this business to continue to grow." That's expansion but is it because demand ahead of preparation? They say "to support the growth we're seeing in that business" (Barry on capital spending). But is customer response running ahead of what they prepared for? They mention growth but not that it exceeded expectations. Also flexibles is a significant part of consumer packaging, not necessarily small relative to total? Consumer packaging is a large segment. So likely no. EvoCan: "we're putting in a new what we call an EvoCan line at our composite can plant in Chicago... that will start up later, the latter part of this year and we see a lot of interest in that when we go through these i6 initiatives" - interest, not current uptake. Also future. i6: "i6 is generating tremendous interest. We have over 30 customer engagements today" - that's interest, not orders. Also not small? It's a process.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
HCKT · Q1 2024 → YESThe question is about whether management describes one identifiable offering that's still small, where customer response is ahead of what they prepared for, AND they're responding now by putting more ...YES The transcript describes AI Explorer (the GenAI assessment platform) as a small, early-stage offering (nominal Q1 revenue impact, part of broader GenAI pivot). Management states customer response is exceeding preparation: "over 175 demo meetings with many more scheduled... resulted in a number of new enterprise...
SYY · Q1 2023 → YESThe question is about whether management describes one identifiable offering or initiative that's still a smaller part of the business, where customer response is running ahead of what they prepared f...YES The transcript shows that Sysco Your Way is presented as a smaller, still-developing offering (described as part of the Recipe For Growth pillars, with its scale expected to grow each quarter and currently limited to specific neighborhoods and recent international rollouts like Toronto and Dublin).
PRPH · Q1 2023 → YESThe question asks if management describes one identifiable offering that's still a smaller part of the business, where customer response is running ahead of what they prepared for, AND they're respond...YES The lozenge manufacturing facility is the clearest match. It is explicitly described as “the least interesting business we’re developing” and still a smaller slice of overall results (COVID testing was the dominant revenue driver for the prior two years).